August 01, 2022
5 min watch
Save
VIDEO: ‘Hypothesis-generating’ study results presented at ASCO
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Hossein Borghaei, DO, MS, spoke with Healio about findings from the S1800A Lung-MAP substudy and CheckMate 816.
Both studies were presented at ASCO Annual Meeting.
“I don’t think anything was necessarily practice-changing, but [it was] hypothesis-generating and also telling us to look for larger randomized studies to come,” Borghaei, chief of thoracic medical oncology, professor of hematology/oncology, co-director of the Immune Monitoring Facility and Gloria and Edmund M. Dunn chair in thoracic oncology at Fox Chase Cancer Center, said.
References:
- Provencio-Pulla M, et al. Abstract LBA8511. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
- Reckamp KL, et al. Abstract 9004. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Borghaei reports serving as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly and Merck.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.